Valneva SE (EPA:VLA)
France · Delayed Price · Currency is EUR | Market Cap | 657.38M |
| Revenue (ttm) | 196.33M |
| Net Income (ttm) | -67.04M |
| Shares Out | 171.73M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 580,941 |
| Average Volume | 2,694,958 |
| Open | 3.848 |
| Previous Close | 3.828 |
| Day's Range | 3.702 - 3.860 |
| 52-Week Range | 1.730 - 5.420 |
| Beta | 1.01 |
| RSI | 47.89 |
| Earnings Date | Aug 12, 2025 |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.
Financial StatementsNews
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
Saint-Herblain (France), September 3 rd , 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine...
Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy • news
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Monday.
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Monday. Shares of Keurig Dr Pepper Inc. (NASDAQ: KDP) fell sharply during Monday's session after the company announced...
Johnson Fistel Investigates Valneva Following FDA Suspension
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Valneva SE (NASDAQ: VALN) regarding possible violations ...
Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US
Valneva SE VALN stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) suspended the license for Ixchiq, citing four new reports of serious adverse events (SAEs) consistent...
Chikungunya vaccine suspended by US after ‘serious’ side effects emerge
US health authorities have suspended the licence for the Ixchiq vaccine against the chikungunya virus following reports of “serious adverse events”, the drug’s French maker said on Monday. Ixchiq is o...
FDA suspends Valneva's chikungunya vaccine license in the U.S.
The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with immediate effect, the French drugmaker said on Monday.
Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has su...
FDA Suspends Valneva's (VALN) Chikungunya Vaccine Approval Over Safety Issues
FDA Suspends Valneva's (VALN) Chikungunya Vaccine Approval Over Safety Issues
Valneva suspended from marketing chikungunya shot in U.S. over safety concerns
Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its s...
Valneva SE 2025 Q2 - Results - Earnings Call Presentation
Valneva SE (VALN) Q2 2025 Earnings Call Transcript
Valneva reports 1H results; reaffirms FY outlook
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
Saint-Herblain (France), August 12, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half o...
FDA lifts pause on Valneva's chikungunya vaccine in elderly
FDA lifts pause on Valneva's chikungunya vaccine for 60+, updating safety info after review. Read more here.
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCH...
AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate
SEATTLE & HEIDELBERG, Germany--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (...
Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary r...
Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults
The European Union's health regulator has lifted the temporary restriction on the use of French drugmaker Valneva's chikungunya vaccine, Ixchiq, in adults aged 65 and above, following a safety review.
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world's larges...
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
Saint-Herblain (France), June 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors wer...
UK's MHRA suspends Valneva's chikungunya vaccine for elderly
UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat chikungunya, a virus transmitted by mosquitoes, in people aged 65 and above...
Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026
Valneva SE (NASDAQ: VALN) on Thursday announced six-month antibody persistence and safety data for its Phase 2 trial evaluating the safety and immunogenicity of two different dose levels of its singl...